References
- Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003 Sep 4;349(10):931–40. doi: 10.1056/NEJMoa021744
- Canales M, Youssef P, Spong R, et al. Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation. Am J Transplant. 2006 Sep;6(9):2157–63. doi: 10.1111/j.1600-6143.2006.01458.x
- Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003 Dec 11;349(24):2326–33. doi: 10.1056/NEJMoa020009
- Degen DA, Janardan J, Barraclough KA, et al. Predictive performance of different kidney function estimation equations in lung transplant patients. Clin Biochem. 2017 May;50(7–8):385–393. doi: 10.1016/j.clinbiochem.2017.01.008
- Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl. 2004 Feb;10(2):301–9. doi: 10.1002/lt.20017
- Lertjitbanjong P, Thongprayoon C, Cheungpasitporn W, et al. Acute Kidney Injury after Lung Transplantation: A Systematic Review and Meta-Analysis. J Clin Med. 2019 Oct 17;8(10):1713. doi: 10.3390/jcm8101713
- Morath C, Opelz G, Döhler B, Zeier M, Süsal C. Influence of Blood Pressure and Calcineurin Inhibitors on Kidney Function After Heart or Liver Transplantation. Transplantation. 2018 May;102(5):845–852. doi: 10.1097/TP.0000000000002023
- Barraclough K, Menahem SA, Bailey M, Thomson NM. Predictors of decline in renal function after lung transplantation. J Heart Lung Transplant. 2006 Dec;25(12):1431–5. doi: 10.1016/j.healun.2006.09.023
- Paradela de la Morena M, De La Torre Bravos M, Prado RF, et al. Chronic kidney disease after lung transplantation: incidence, risk factors, and treatment. Transplant Proc. 2010 Oct;42(8):3217–9. doi: 10.1016/j.transproceed.2010.05.064
- Tang X, Bergstralh EJ, Mehta RA, Vrtiska TJ, Milliner DS, Lieske JC. Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney Int. 2015 Mar;87(3):623–31. doi: 10.1038/ki.2014.298
- Andoh TF, Bennett WM. Chronic cyclosporine nephrotoxicity. Curr Opin Nephrol Hypertens. 1998 May;7(3):265–70. doi: 10.1097/00041552-199805000-00005
- Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med. 1984 Sep 13;311(11):699–705. doi: 10.1056/NEJM198409133111103
- Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet. 2000 Jul 15;356(9225):194–202. doi: 10.1016/s0140-6736(00)02480-6
- Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant. 2005 Sep;5(9):2273–80. doi: 10.1111/j.1600-6143.2005.01019.x
- Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 Dec 20;357(25):2562–75. doi: 10.1056/NEJMoa067411
- Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant. 2006 Mar;6(3):514–22. doi: 10.1111/j.1600-6143.2005.01177.x
- Dean PG, Grande JP, Sethi S, et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation. 2008 Apr 27;85(8):1212–5. doi: 10.1097/TP.0b013e31816a8ae6
- Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant. 2011 Aug;11(8):1633–44. doi: 10.1111/j.1600-6143.2011.03573.x
- Heilman RL, Cortese C, Geiger XJ, et al. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal. Transplantation. 2012 Jan 15;93(1):47–53. doi: 10.1097/TP.0b013e3182394cb3
- Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010 Mar;10(3):547–57. doi: 10.1111/j.1600-6143.2010.03016.x
- Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010 Mar;10(3):535–46. doi: 10.1111/j.1600-6143.2009.03005.x
- Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant. 2009 May;9(5):1115–23. doi: 10.1111/j.1600-6143.2009.02615.x
- Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int. 2011 Apr;79(8):897–907. doi: 10.1038/ki.2010.492
- Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009 Jan 27;87(2):233–42. doi: 10.1097/TP.0b013e3181927a41
- Ekberg H, Grinyó J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007 Mar;7(3):560–70. doi: 10.1111/j.1600-6143.2006.01645.x
- Ishani A, Erturk S, Hertz MI, Matas AJ, Savik K, Rosenberg ME. Predictors of renal function following lung or heart-lung transplantation. Kidney Int. 2002 Jun;61(6):2228–34. doi: 10.1046/j.1523-1755.2002.00361.x
- The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997 Nov 24;157(21):2413–46. doi: 10.1001/archinte.157.21.2413
- Randhawa P, Brennan DC. BK virus infection in transplant recipients: an overview and update. Am J Transplant. 2006 Sep;6(9):2000–5. doi: 10.1111/j.1600-6143.2006.01403.x
- Aweeka FT, Jacobson MA, Martin-Munley S, et al. Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):350–7. doi: 10.1097/00042560-199904010-00005
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1–266. PMID: 11904577
- Cheung AK, Chang TI, Cushman WC, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 Mar;99(3):559–569. doi: 10.1016/j.kint.2020.10.026
- Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006 Jun;6(6):1377–86. doi: 10.1111/j.1600-6143.2006.01290.x
DOI: https://doi.org/10.14797/mdcvj.1122 | Journal eISSN: 1947-6108
Language: English
Page range: 34 - 40
Submitted on: Apr 20, 2022
Accepted on: Jul 12, 2022
Published on: Sep 6, 2022
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2022 Carlos M. Zapata, Hassan N. Ibrahim, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.